Cargando…

Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution

BACKGROUND: Vaccination of macaques with live attenuated simian immunodeficiency virus (SIV) provides significant protection against the wild-type virus. The use of a live attenuated human immunodeficiency virus (HIV) as AIDS vaccine in humans is however considered unsafe because of the risk that th...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Atze T, Klaver, Bep, Centlivre, Mireille, Harwig, Alex, Ooms, Marcel, Page, Mark, Almond, Neil, Yuan, Fang, Piatak, Mike, Lifson, Jeffrey D, Berkhout, Ben
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443169/
https://www.ncbi.nlm.nih.gov/pubmed/18533993
http://dx.doi.org/10.1186/1742-4690-5-44
_version_ 1782156807835222016
author Das, Atze T
Klaver, Bep
Centlivre, Mireille
Harwig, Alex
Ooms, Marcel
Page, Mark
Almond, Neil
Yuan, Fang
Piatak, Mike
Lifson, Jeffrey D
Berkhout, Ben
author_facet Das, Atze T
Klaver, Bep
Centlivre, Mireille
Harwig, Alex
Ooms, Marcel
Page, Mark
Almond, Neil
Yuan, Fang
Piatak, Mike
Lifson, Jeffrey D
Berkhout, Ben
author_sort Das, Atze T
collection PubMed
description BACKGROUND: Vaccination of macaques with live attenuated simian immunodeficiency virus (SIV) provides significant protection against the wild-type virus. The use of a live attenuated human immunodeficiency virus (HIV) as AIDS vaccine in humans is however considered unsafe because of the risk that the attenuated virus may accumulate genetic changes during persistence and evolve to a pathogenic variant. We earlier presented a conditionally live HIV-1 variant that replicates exclusively in the presence of doxycycline (dox). Replication of this vaccine strain can be limited to the time that is needed to provide full protection through transient dox administration. Since the effectiveness and safety of such a conditionally live virus vaccine should be tested in macaques, we constructed a similar dox-dependent SIV variant. The Tat-TAR transcription control mechanism in this virus was inactivated through mutation and functionally replaced by the dox-inducible Tet-On regulatory system. This SIV-rtTA variant replicated in a dox-dependent manner in T cell lines, but not as efficiently as the parental SIVmac239 strain. Since macaque studies will likely require an efficiently replicating variant, we set out to optimize SIV-rtTA through in vitro viral evolution. RESULTS: Upon long-term culturing of SIV-rtTA, additional nucleotide substitutions were observed in TAR that affect the structure of this RNA element but that do not restore Tat binding. We demonstrate that the bulge and loop mutations that we had introduced in the TAR element of SIV-rtTA to inactivate the Tat-TAR mechanism, shifted the equilibrium between two alternative conformations of TAR. The additional TAR mutations observed in the evolved variants partially or completely restored this equilibrium, which suggests that the balance between the two TAR conformations is important for efficient viral replication. Moreover, SIV-rtTA acquired mutations in the U3 promoter region. We demonstrate that these TAR and U3 changes improve viral replication in T-cell lines and macaque peripheral blood mononuclear cells (PBMC) but do not affect dox-control. CONCLUSION: The dox-dependent SIV-rtTA variant was optimized by viral evolution, yielding variants that can be used to test the conditionally live virus vaccine approach and as a tool in SIV biology studies and vaccine research.
format Text
id pubmed-2443169
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24431692008-07-04 Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution Das, Atze T Klaver, Bep Centlivre, Mireille Harwig, Alex Ooms, Marcel Page, Mark Almond, Neil Yuan, Fang Piatak, Mike Lifson, Jeffrey D Berkhout, Ben Retrovirology Research BACKGROUND: Vaccination of macaques with live attenuated simian immunodeficiency virus (SIV) provides significant protection against the wild-type virus. The use of a live attenuated human immunodeficiency virus (HIV) as AIDS vaccine in humans is however considered unsafe because of the risk that the attenuated virus may accumulate genetic changes during persistence and evolve to a pathogenic variant. We earlier presented a conditionally live HIV-1 variant that replicates exclusively in the presence of doxycycline (dox). Replication of this vaccine strain can be limited to the time that is needed to provide full protection through transient dox administration. Since the effectiveness and safety of such a conditionally live virus vaccine should be tested in macaques, we constructed a similar dox-dependent SIV variant. The Tat-TAR transcription control mechanism in this virus was inactivated through mutation and functionally replaced by the dox-inducible Tet-On regulatory system. This SIV-rtTA variant replicated in a dox-dependent manner in T cell lines, but not as efficiently as the parental SIVmac239 strain. Since macaque studies will likely require an efficiently replicating variant, we set out to optimize SIV-rtTA through in vitro viral evolution. RESULTS: Upon long-term culturing of SIV-rtTA, additional nucleotide substitutions were observed in TAR that affect the structure of this RNA element but that do not restore Tat binding. We demonstrate that the bulge and loop mutations that we had introduced in the TAR element of SIV-rtTA to inactivate the Tat-TAR mechanism, shifted the equilibrium between two alternative conformations of TAR. The additional TAR mutations observed in the evolved variants partially or completely restored this equilibrium, which suggests that the balance between the two TAR conformations is important for efficient viral replication. Moreover, SIV-rtTA acquired mutations in the U3 promoter region. We demonstrate that these TAR and U3 changes improve viral replication in T-cell lines and macaque peripheral blood mononuclear cells (PBMC) but do not affect dox-control. CONCLUSION: The dox-dependent SIV-rtTA variant was optimized by viral evolution, yielding variants that can be used to test the conditionally live virus vaccine approach and as a tool in SIV biology studies and vaccine research. BioMed Central 2008-06-05 /pmc/articles/PMC2443169/ /pubmed/18533993 http://dx.doi.org/10.1186/1742-4690-5-44 Text en Copyright © 2008 Das et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Das, Atze T
Klaver, Bep
Centlivre, Mireille
Harwig, Alex
Ooms, Marcel
Page, Mark
Almond, Neil
Yuan, Fang
Piatak, Mike
Lifson, Jeffrey D
Berkhout, Ben
Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title_full Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title_fullStr Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title_full_unstemmed Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title_short Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
title_sort optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443169/
https://www.ncbi.nlm.nih.gov/pubmed/18533993
http://dx.doi.org/10.1186/1742-4690-5-44
work_keys_str_mv AT dasatzet optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT klaverbep optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT centlivremireille optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT harwigalex optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT oomsmarcel optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT pagemark optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT almondneil optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT yuanfang optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT piatakmike optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT lifsonjeffreyd optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution
AT berkhoutben optimizationofthedoxycyclinedependentsimianimmunodeficiencyvirusthroughinvitroevolution